F. Socolow

First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: a single-arm, single-centre, phase 2 trial.

M. Berger, Laura H. Tang, D. Solit, 2023, The Lancet. Oncology.

Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer

N. Schultz, D. Solit, U. Bhanot, 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.